Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stephen A. Cannistra, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA060670 (CANNISTRA, STEPHEN A) Aug 1, 1993 - May 31, 1998
    NIH/NCI
    ADHESION PROTEIN AND OVARIAN CANCER IMPLANTATION
    Role: Principal Investigator
  2. F32CA007765 (CANNISTRA, STEPHEN A) Jul 17, 1985
    NIH/NCI
    ROLE OF IA ANTIGENS IN REGULATION OF HUMAN MYELOPOIESIS
    Role: Principal Investigator
  3. M01RR001032 (SUKHATME, VIKAS P) Dec 1, 1977 - Mar 31, 2010
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cannistra SA. In the Pursuit of Excellence: Reflections From the Editor-in-Chief of Journal of Clinical Oncology. J Clin Oncol. 2016 Oct 20; 34(30):3589-3590. PMID: 27621398.
    View in: PubMed
  2. Zerillo JA, Cannistra SA, Totte C. Raising the safety bar: The hematology/oncology patient safety committee. J Clin Oncol. 2014 Oct 20; 32(30_suppl):144. PMID: 28141286.
    View in: PubMed
  3. Liu JF, Cannistra SA. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 01; 32(13):1287-9. PMID: 24637996.
    View in: PubMed
  4. Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA. Reply to C.M. Booth et al. J Clin Oncol. 2013 Sep 10; 31(26):3300. PMID: 23943837.
    View in: PubMed
  5. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4. PMID: 23358984.
    View in: PubMed
  6. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1. PMID: 22366591.
    View in: PubMed
  7. Konstantinopoulos PA, Cannistra SA. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J Clin Oncol. 2012 Feb 01; 30(4):347-50. PMID: 22203759.
    View in: PubMed
  8. Janco JM, Hacker MR, Konstantinopoulos PA, Cannistra SA, Awtrey CS. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer. J Minim Invasive Gynecol. 2011 Sep-Oct; 18(5):629-33. PMID: 21803662.
    View in: PubMed
  9. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res. 2011 Aug 01; 71(15):5081-9. PMID: 21676886.
    View in: PubMed
  10. Cannistra SA. New initiatives at Journal of Clinical Oncology. J Clin Oncol. 2011 Jul 01; 29(19):2609-10. PMID: 21646608.
    View in: PubMed
  11. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 2011 Mar 29; 6(3):e18202. PMID: 21479231; PMCID: PMC3066217.
  12. Verweij J, Disis ML, Cannistra SA. Phase I studies of drug combinations. J Clin Oncol. 2010 Oct 20; 28(30):4545-6. PMID: 20855831.
    View in: PubMed
  13. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010 Aug 01; 28(22):3555-61. PMID: 20547991; PMCID: PMC2917311.
  14. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol. 2010 Jul 01; 28(19):3101-3. PMID: 20516442.
    View in: PubMed
  15. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9. PMID: 19917843.
    View in: PubMed
  16. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6. PMID: 19826113; PMCID: PMC2792954.
  17. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol. 2009 Jul 01; 27(19):3073-6. PMID: 19451415.
    View in: PubMed
  18. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics. 2008 Nov 28; 1:59. PMID: 19038057; PMCID: PMC2613398.
  19. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol. 2008 Aug 01; 26(22):3665-7. PMID: 18669449.
    View in: PubMed
  20. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008 Oct; 5(10):577-87. PMID: 18648354.
    View in: PubMed
  21. Cannistra SA. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease. Clin Cancer Res. 2007 Dec 15; 13(24):7225-7. PMID: 18094398.
    View in: PubMed
  22. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20; 25(33):5180-6. PMID: 18024865.
    View in: PubMed
  23. Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007 Sep; 14(3):781-90. PMID: 17914107.
    View in: PubMed
  24. Comander AH, Cannistra SA. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):51-8. PMID: 17506844.
    View in: PubMed
  25. Cannistra SA. Performance of biopsies in clinical research. J Clin Oncol. 2007 Apr 10; 25(11):1454-5. PMID: 17416872.
    View in: PubMed
  26. Cannistra SA. Gynecologic oncology or medical oncology: what's in a name? J Clin Oncol. 2007 Apr 01; 25(10):1157-9. PMID: 17401003.
    View in: PubMed
  27. Cannistra SA, Matulonis U, Penson R, Wenham R, Armstrong D, Burger RA, Mackey H, Douglas J, Hambleton J, McGuire W. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5006. PMID: 27952183.
    View in: PubMed
  28. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020. PMID: 27952190.
    View in: PubMed
  29. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med. 2006 Jan 05; 354(1):77-9. PMID: 16394306.
    View in: PubMed
  30. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005 Nov 01; 23(31):7911-8. PMID: 16204010.
    View in: PubMed
  31. Berkenblit A, Cannistra SA. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2005 Jun; 50(6):426-38. PMID: 16050567.
    View in: PubMed
  32. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004 Dec 09; 351(24):2519-29. PMID: 15590954.
    View in: PubMed
  33. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31. PMID: 15581974.
    View in: PubMed
  34. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004 Dec 01; 22(23):4700-10. PMID: 15505275.
    View in: PubMed
  35. Cannistra SA. The ethics of early stopping rules: who is protecting whom? J Clin Oncol. 2004 May 01; 22(9):1542-5. PMID: 15117977.
    View in: PubMed
  36. Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA. Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin. Gynecol Oncol. 2003 Jun; 89(3):486-93. PMID: 12798716.
    View in: PubMed
  37. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003 May 15; 21(10 Suppl):129s-132s. PMID: 12743127.
    View in: PubMed
  38. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003 Mar 15; 21(6):1180-9. PMID: 12637488.
    View in: PubMed
  39. Cannistra SA. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 2002 Mar 01; 20(5):1158-60. PMID: 11870154.
    View in: PubMed
  40. Raffel GD, Gravallese EM, Schwab P, Joseph JT, Cannistra SA. Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer. J Clin Oncol. 2001 Dec 01; 19(23):4341-3. PMID: 11731518.
    View in: PubMed
  41. Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T, Sugano K, Cannistra SA, Clinton SK, Maher ER, Prior TW, Eng C. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum Genet. 2001 Aug; 109(2):146-51. PMID: 11511919.
    View in: PubMed
  42. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001 Jun; 158(6):2097-106. PMID: 11395387; PMCID: PMC1891985.
  43. Cannistra SA. When is a "prognostic factor" really prognostic? J Clin Oncol. 2000 Nov 15; 18(22):3745-7. PMID: 11078486.
    View in: PubMed
  44. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000 Aug 01; 165(3):1705-11. PMID: 10903782.
    View in: PubMed
  45. Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2000 May; 77(2):271-7. PMID: 10785477.
    View in: PubMed
  46. Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999 Jun; 73(3):362-7. PMID: 10366461.
    View in: PubMed
  47. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 1999 May 01; 59(9):2121-6. PMID: 10232598.
    View in: PubMed
  48. Cannistra SA. Back to the future: multiagent chemotherapy in ovarian cancer revisited. J Clin Oncol. 1999 Mar; 17(3):741-3. PMID: 10071260.
    View in: PubMed
  49. Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene. 1998 Nov 12; 17(19):2419-27. PMID: 9824152.
    View in: PubMed
  50. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 1998 Nov 01; 58(21):4776-81. PMID: 9809975.
    View in: PubMed
  51. Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer. 1998 Aug 31; 77(5):741-6. PMID: 9688308.
    View in: PubMed
  52. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998 Aug; 16(8):2583-90. PMID: 9704707.
    View in: PubMed
  53. Cannistra SA. "Cancer defeated": not if, but when--introducing the Biology of Neoplasia series. J Clin Oncol. 1997 Nov; 15(11):3297-8. PMID: 9363857.
    View in: PubMed
  54. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene. 1997 Jun 12; 14(23):2753-8. PMID: 9190890.
    View in: PubMed
  55. Cannistra SA. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med. 1997 Apr 24; 336(17):1254; author reply 1256-7. PMID: 9121519.
    View in: PubMed
  56. Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997 Apr 01; 57(7):1228-32. PMID: 9102203.
    View in: PubMed
  57. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14094-9. PMID: 8943066; PMCID: PMC19500.
  58. Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer. 1996 Aug; 74(3):446-52. PMID: 8695362; PMCID: PMC2074650.
  59. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med. 1996 Apr 18; 334(16):1030-8. PMID: 8598842.
    View in: PubMed
  60. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science. 1996 Apr 05; 272(5258):123-6. PMID: 8600523.
    View in: PubMed
  61. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996 Feb; 60(2):301-7. PMID: 8631556.
    View in: PubMed
  62. Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, Ottensmeier C. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol. 1995 Aug; 13(8):1912-21. PMID: 7543560.
    View in: PubMed
  63. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol. 1995 Aug; 58(2):216-25. PMID: 7542622.
    View in: PubMed
  64. Cannistra SA. Interval cytoreduction in ovarian cancer. N Engl J Med. 1995 Jul 27; 333(4):255. PMID: 7791845.
    View in: PubMed
  65. Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res. 1995 Mar; 1(3):333-42. PMID: 9815989.
    View in: PubMed
  66. Cannistra SA, Ottensmeier C, Tidy J, DeFranzo B. Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes. Exp Hematol. 1994 Sep; 22(10):996-1002. PMID: 7522188.
    View in: PubMed
  67. Cannistra SA. Paclitaxel in ovarian cancer: how can we make it better? J Clin Oncol. 1994 Sep; 12(9):1743-4. PMID: 7916037.
    View in: PubMed
  68. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993 Nov 18; 329(21):1550-9. PMID: 8155119.
    View in: PubMed
  69. Cannistra SA. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol. 1993 Nov; 51(2):292-4. PMID: 8276314.
    View in: PubMed
  70. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993 Aug 15; 53(16):3830-8. PMID: 8339295.
    View in: PubMed
  71. Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol. 1993 Aug; 11(8):1583-91. PMID: 8101563.
    View in: PubMed
  72. Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102. PMID: 8342558.
    View in: PubMed
  73. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood. 1992 Nov 01; 80(9):2306-14. PMID: 1421401.
    View in: PubMed
  74. Koenigsmann M, Griffin JD, DiCarlo J, Cannistra SA. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 1992 Feb 01; 79(3):657-65. PMID: 1370640.
    View in: PubMed
  75. Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosise WW, Hawkins JC, Kaushansky K, Griffin JD. Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991 Mar 01; 77(5):1033-43. PMID: 1704802.
    View in: PubMed
  76. Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ, Griffin JD. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8. PMID: 1826536.
    View in: PubMed
  77. Cannistra SA. Why should the clonogenic cell assay be prognostically important in ovarian cancer? J Clin Oncol. 1991 Mar; 9(3):368-70. PMID: 1999705.
    View in: PubMed
  78. Cannistra SA. Growth regulation of malignant clonogenic cells in acute myeloid leukemia. Curr Opin Oncol. 1991 Feb; 3(1):4-12. PMID: 1828375.
    View in: PubMed
  79. Kanakura Y, Druker B, DiCarlo J, Cannistra SA, Griffin JD. Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem. 1991 Jan 05; 266(1):490-5. PMID: 1845978.
    View in: PubMed
  80. Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990 Aug 15; 76(4):706-15. PMID: 2166606.
    View in: PubMed
  81. Cannistra SA, Koenigsmann M, DiCarlo J, Groshek P, Griffin JD. Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem. 1990 Jul 25; 265(21):12656-63. PMID: 2165070.
    View in: PubMed
  82. Dadmarz R, Rabinowe SN, Cannistra SA, Andersen JW, Freedman AS, Nadler LM. Association between clonogenic cell growth and clinical risk group in B-cell chronic lymphocytic leukemia. Blood. 1990 Jul 01; 76(1):142-9. PMID: 2194588.
    View in: PubMed
  83. Cannistra SA. Chronic myelogenous leukemia as a model for the genetic basis of cancer. Hematol Oncol Clin North Am. 1990 Apr; 4(2):337-57. PMID: 2182595.
    View in: PubMed
  84. Roy DC, Felix M, Cannady WG, Cannistra S, Ritz J. Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res. 1990; 14(5):407-16. PMID: 2345466.
    View in: PubMed
  85. Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y. The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5. PMID: 2157777.
    View in: PubMed
  86. Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):93-7. PMID: 2153304; PMCID: PMC53206.
  87. Griffin JD, Demetri GD, Kanakura Y, Cannistra SA, Ernst TJ. Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41. PMID: 2189136.
    View in: PubMed
  88. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989 May; 3(5):328-34. PMID: 2654494.
    View in: PubMed
  89. Herrmann F, Cannistra SA, Lindemann A, Blohm D, Rambaldi A, Mertelsmann RH, Griffin JD. Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol. 1989 Jan 01; 142(1):139-43. PMID: 2491871.
    View in: PubMed
  90. Herrmann F, Lindemann A, Cannistra SA, Brach M, Oster W, Griffin JD, Mertelsmann R. Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. Haematol Blood Transfus. 1989; 32:299-315. PMID: 2516496.
    View in: PubMed
  91. Cannistra SA, Groshek P, Griffin JD. Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. Exp Hematol. 1988 Nov; 16(10):865-70. PMID: 3139436.
    View in: PubMed
  92. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8. PMID: 3045544.
    View in: PubMed
  93. Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7. PMID: 3042045.
    View in: PubMed
  94. Cannistra SA, Griffin JD. Regulation of the production and function of granulocytes and monocytes. Semin Hematol. 1988 Jul; 25(3):173-88. PMID: 3043672.
    View in: PubMed
  95. Young DC, Demetri GD, Ernst TJ, Cannistra SA, Griffin JD. In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82. PMID: 2453374.
    View in: PubMed
  96. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009.
    View in: PubMed
  97. Cannistra SA, Vellenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 1988 Mar; 71(3):672-6. PMID: 3278752.
    View in: PubMed
  98. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987 Oct; 70(4):1218-21. PMID: 3498521.
    View in: PubMed
  99. Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8. PMID: 3294900.
    View in: PubMed
  100. Rambaldi A, Young DC, Herrmann F, Cannistra SA, Griffin JD. Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan; 17(1):153-6. PMID: 3102253.
    View in: PubMed
  101. Herrmann F, Cannistra SA, Griffin JD. T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol. 1986 Apr 15; 136(8):2856-61. PMID: 3082974.
    View in: PubMed
  102. Cannistra SA, Herrmann F, Davis R, Nichols K, Griffin JD. Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest. 1986 Jan; 77(1):13-20. PMID: 3455931; PMCID: PMC423301.
  103. Griffin JD, Sabbath KD, Herrmann F, Larcom P, Nichols K, Kornacki M, Levine H, Cannistra SA. Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood. 1985 Oct; 66(4):788-95. PMID: 3929858.
    View in: PubMed
  104. Herrmann F, Cannistra SA, Levine H, Griffin JD. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 01; 162(3):1111-6. PMID: 3928803; PMCID: PMC2187806.
  105. Cannistra SA, Daley JF, Larcom P, Griffin JD. Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. Blood. 1985 Feb; 65(2):414-22. PMID: 3855362.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Cannistra's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (439)
Explore
_
Co-Authors (42)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.